Combining ACOX1-specific inhibitors with middle- or low-dose OCA effectively improved liver function and reduced LDL and steatohepatitis in mice, indicating that targeting ACOX1 could be a promising therapeutic strategy for NAFLD when used in conjunction with FXR agonists. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.